India has rejected Abbott's patent application for lopinavir/ritonavir

Indian patent office has rejected the patent application of Abbott for its lifesaving HIV drug combo of lopinavir/ritonavir.
Abbott has already granted patent in many countries throughout the world for this combination but india has rejected this application based on the combination of existing drug is not an invention and considering it as a patent evergreening strategy only.
Such type of patent will hinder the entry of generic players in the market and which will lead to only suffering of patients.

Intas pharmaceutical is set to enter capital market witrh giant IPO

Intas Pharmaceuticals, a Rs.1,600 crore pharma giant from Ahmedabad, has decided to enter capital market in May next year to raise Rs.750-800 crore through public issue. This will help to raise fresh funds for acquisitions besides allowing private equity (PE) investor ChrysCapital to partly exit, a top company executive said to Chronicle Pharmabiz.

Intas is looking to sell around 15 per cent stake that will value it over Rs.5,000 crore. The issue, expected around May next year, will be the biggest in the pharma sector in several years. The Rs.1,00,000 crore drug industry has not seen listing of any notable companies since Zydus Cadila's share sale ten years ago to raise Rs.372 crore.
For full story click here